Duration of Antiviral Prophylaxis and Risk of Herpes Zoster among Patients Receiving Autologous Hematopoietic Stem Cell Transplants: A Retrospective, Observational Study

Advances in Therapy
Dongmu ZhangLynn Finelli

Abstract

There are no real-world data on antiviral prophylaxis (AP) duration and risk of herpes zoster (HZ) given AP duration in patients receiving autologous hematopoietic stem cell transplants (auto-HSCT). The objectives of this study are to describe the duration of AP and to compare incidence of HZ by AP duration in auto-HSCT patients. This is a retrospective, observational database (Marketscan®) study. This study included patients ≥18 years old who had auto-HSCT during 2009-2013, had chemotherapy within 60 days prior to auto-HSCT (latest chemotherapy date within the 60 days was the study enrollment date), and had continuous health plan enrollment for at least 365 days before and after the study enrollment date. AP duration was the sum of days supply of all AP prescriptions from 30 days before to 365 days after the study enrollment date. Patients were followed from the study enrollment date to the end of continuous health plan enrollment, death, or December 31, 2014 to assess HZ incidence. The Cox proportional hazards model was used to examine the association between the risk of HZ and AP duration. This study identified 1959 eligible auto-HSCT patients, of whom 93.0% were prescribed AP. Average AP duration was 220 days (SD = 122), wh...Continue Reading

References

Aug 2, 2002·The New England Journal of Medicine·John W Gnann, Richard J Whitley
Apr 5, 2003·BMJ : British Medical Journal·Robert W Johnson, Robert H Dworkin
Feb 26, 2004·Epidemiology and Infection·D M FlemingR S Chapman
Jul 30, 2005·Journal of General Internal Medicine·Ralph P InsingaAlexander A Nikas
Jan 24, 2006·Lancet·Ralf Baron, Gunnar Wasner
Sep 15, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marcie TomblynUNKNOWN Centers for Disease Control and Prevention
Oct 28, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Shih Hann SuJean Roy
Jun 21, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Abdirahman MahamudStephanie R Bialek
Nov 10, 2012·Journal of the National Comprehensive Cancer Network : JNCCN·Lindsey Robert BadenUNKNOWN National Comprehensive Cancer Network
Mar 1, 2014·The Western Journal of Emergency Medicine·Bharath ChakravarthyShahram Lotfipour
Nov 8, 2015·BMC Infectious Diseases·Barbara H JohnsonCamilo J Acosta

❮ Previous
Next ❯

Citations

Nov 5, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Susannah L McKayKathleen Dooling
Jul 10, 2019·JAMA : the Journal of the American Medical Association·Adriana BastidasUNKNOWN ZOE-HSCT Study Group Collaborators
Jun 12, 2021·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Marta López-FauquedFernanda Tavares-da-Silva

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.